284 related articles for article (PubMed ID: 10697073)
21. Treatment of Parkinson's disease : what's on the horizon?
Wu SS; Frucht SJ
CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
[TBL] [Abstract][Full Text] [Related]
22. Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease.
Gao Y; Chu SF; Li JP; Zhang Z; Yan JQ; Wen ZL; Xia CY; Mou Z; Wang ZZ; He WB; Guo XF; Wei GN; Chen NH
Acta Pharmacol Sin; 2015 Mar; 36(3):311-22. PubMed ID: 25640478
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases.
Yang X; Zhang Y; Xu H; Luo X; Yu J; Liu J; Chang RC
Curr Top Med Chem; 2016; 16(8):858-66. PubMed ID: 26311425
[TBL] [Abstract][Full Text] [Related]
24. New therapeutic strategy for Parkinson's and Alzheimer's disease.
Esposito E; Cuzzocrea S
Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
[TBL] [Abstract][Full Text] [Related]
25. Clinical potential of minocycline for neurodegenerative disorders.
Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
[TBL] [Abstract][Full Text] [Related]
26. Striatal calcium channel antagonist receptors in Huntington's disease and Parkinson's disease.
Watson DL; Carpenter CL; Marks SS; Greenberg DA
Ann Neurol; 1988 Mar; 23(3):303-5. PubMed ID: 2967667
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.
Bodner RA; Outeiro TF; Altmann S; Maxwell MM; Cho SH; Hyman BT; McLean PJ; Young AB; Housman DE; Kazantsev AG
Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4246-51. PubMed ID: 16537516
[TBL] [Abstract][Full Text] [Related]
28. Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?
Jodeiri Farshbaf M; Ghaedi K
Biometals; 2017 Feb; 30(1):1-16. PubMed ID: 27853903
[TBL] [Abstract][Full Text] [Related]
29. Coenzyme Q10: a review of its promise as a neuroprotectant.
Young AJ; Johnson S; Steffens DC; Doraiswamy PM
CNS Spectr; 2007 Jan; 12(1):62-8. PubMed ID: 17192765
[TBL] [Abstract][Full Text] [Related]
30. Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
Olney JW; Zorumski CF; Stewart GR; Price MT; Wang GJ; Labruyere J
Exp Neurol; 1990 Jun; 108(3):269-72. PubMed ID: 1972067
[TBL] [Abstract][Full Text] [Related]
31. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
Glass M; Dragunow M; Faull RL
Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
[TBL] [Abstract][Full Text] [Related]
32. Current therapeutic advances in patients and experimental models of Huntington's disease.
Brett AC; Rosenstock TR; Rego AC
Curr Drug Targets; 2014 Mar; 15(3):313-34. PubMed ID: 24266585
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of simple and choice reaction time in Parkinson's, Huntington's and cerebellar disease.
Jahanshahi M; Brown RG; Marsden CD
J Neurol Neurosurg Psychiatry; 1993 Nov; 56(11):1169-77. PubMed ID: 8229028
[TBL] [Abstract][Full Text] [Related]
34. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases.
Outeiro TF; Giorgini F
Biotechnol J; 2006 Mar; 1(3):258-69. PubMed ID: 16897706
[TBL] [Abstract][Full Text] [Related]
35. Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease.
Cisbani G; Maxan A; Kordower JH; Planel E; Freeman TB; Cicchetti F
Brain; 2017 Nov; 140(11):2982-2992. PubMed ID: 29069396
[TBL] [Abstract][Full Text] [Related]
36. Neuropsychiatry of Huntington's disease and other basal ganglia disorders.
Rosenblatt A; Leroi I
Psychosomatics; 2000; 41(1):24-30. PubMed ID: 10665265
[TBL] [Abstract][Full Text] [Related]
37. Antiglutamate therapies in Huntington's disease.
Kieburtz K
J Neural Transm Suppl; 1999; 55():97-102. PubMed ID: 10335496
[TBL] [Abstract][Full Text] [Related]
38. [A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy].
Pupyshev AB; Korolenko TA; Tikhonova MA
Zh Vyssh Nerv Deiat Im I P Pavlova; 2016 Sep; 66(5):515-540. PubMed ID: 30695399
[TBL] [Abstract][Full Text] [Related]
39. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.
Klivenyi P; Ferrante RJ; Gardian G; Browne S; Chabrier PE; Beal MF
J Neurochem; 2003 Jul; 86(1):267-72. PubMed ID: 12807446
[TBL] [Abstract][Full Text] [Related]
40. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
Beal MF
Ann Neurol; 1992 Feb; 31(2):119-30. PubMed ID: 1349466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
